The treatment of retinoblastoma (Rb) has not been optimized and we have preliminary data suggesting that targeting the pro-survival molecule, surviving, may be an effective strategy for enhancing the therapeutic responsiveness of Rb. We will examine surviving expression partners for Rb cells and tumor lines exposed to standard chemotherapy and radiation. We will also combine current treatment protocols with small molecule inhibitors of surviving using intraocular tumor models of Rb.

NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.